Xeris Biopharma Holdings Inc.

06/05/2026 | Press release | Distributed by Public on 06/05/2026 14:14

Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 4, 2026, Xeris Biopharma Holdings, Inc. (the "Company") held its 2026 Annual Meeting of Stockholders (the "Annual Meeting"). As of the close of business on April 14, 2026, the record date for the Annual Meeting, there were 172,625,762 shares of the Company's common stock outstanding and entitled to vote at the Annual Meeting, of which 128,268,073 shares were present in person virtually or represented by proxy at the Annual Meeting, constituting a quorum on all matters voted upon. Shares present virtually during the Annual Meeting were considered shares represented in person at the Annual Meeting. The final voting results of the Annual Meeting are as follows:
Proposal One: Election of Directors
As described in the Company's Definitive Proxy Statement on Schedule 14A, filed on April 23, 2026 (the "Proxy Statement"), the Company's Board of Directors nominated two individuals to serve as Class II directors until the Company's 2029 Annual Meeting of Stockholders, or until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation, or removal. Each nominee was elected by a plurality vote in accordance with the Company's Amended and Restated Bylaws, as follows:
Class II Director Nominee For Withhold Broker Non-Votes
Dawn Halkuff 62,581,577 24,906,166 40,780,330
John Johnson 52,665,077 34,822,666 40,780,330
Proposal Two: Ratification of Appointment of Independent Registered Public Accounting Firm
The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026:
For Against Abstain Broker Non-Votes
125,789,818 1,032,530 1,445,725 -
Proposal Three: Advisory Vote to Approve Named Executive Officer Compensation
The Company's stockholders approved, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission (the "Say-on-Pay Vote"). The Company's stockholders voted as follows to approve such executive compensation for the Company's named executive officers pursuant to the Say-on-Pay Vote:
For Against Abstain Broker Non-Votes
82,230,204 4,658,035 599,504 40,780,330
No other matters were submitted to or voted on by the Company's stockholders at the Annual Meeting.
Xeris Biopharma Holdings Inc. published this content on June 05, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on June 05, 2026 at 20:14 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]